Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
HER2 acts an oncogenic driver in numerous cancers. Here, the authors design an anti-HER2 biparatopic and tetravalent IgG fusion with inhibitory effects in a xenograft model.
Guardado en:
Autores principales: | Florian Kast, Martin Schwill, Jakob C. Stüber, Svende Pfundstein, Gabriela Nagy-Davidescu, Josep M. Monné Rodríguez, Frauke Seehusen, Christian P. Richter, Annemarie Honegger, Karen Patricia Hartmann, Thomas G. Weber, Felix Kroener, Patrick Ernst, Jacob Piehler, Andreas Plückthun |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bbc4cba63fcc425a86335df0941f73d7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS–p110 crosstalk
por: Rastislav Tamaskovic, et al.
Publicado: (2016) -
Apoptosis-inducing anti-HER2 agents operate through oligomerization-induced receptor immobilization
por: Jakob C. Stüber, et al.
Publicado: (2021) -
A Tetravalent Biparatopic Antibody Causes Strong HER2 Internalization and Inhibits Cellular Proliferation
por: Filippo Benedetti, et al.
Publicado: (2021) -
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Avisek Majumder, et al.
Publicado: (2021) -
Multimodal Imaging Technology Effectively Monitors HER2 Expression in Tumors Using Trastuzumab-Coupled Organic Nanoparticles in Patient-Derived Xenograft Mice Models
por: Li Wen, et al.
Publicado: (2021)